Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMTYD8Q)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Talibegron hydrochloride; ZD 2079; 178600-17-4; Talibegron HCl; ICID2079; UNII-N251Q608VU; ZD-2079; Talibegron hydrochloride [USAN]; ZD2079; SCH 417849; N251Q608VU; NCGC00092315-01; 4-[2-[[(2R)-2-HYDROXY-2-PHENYLETHYL]AMINO]ETHOXY]-BENZENEACETIC ACID HYDROCHLORIDE; DSSTox_RID_83233; DSSTox_CID_28968; DSSTox_GSID_49042; Talibegron hydrochloride (USAN); Benzeneacetic acid, 4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethoxy)-, hydrochloride; CAS-178600-17-4; Talibegron hydrochloride; ZD 2079 hydrochloride; AC1L4KMI; C18H21NO4.HCl
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
